Oruka (ORKA) CMO Joana Goncalves Exercises Options, Sells Shares

What Happened
Joana Goncalves, Chief Medical Officer of Oruka Therapeutics (ORKA), reported exercising derivatives to acquire a total of 7,000 shares and simultaneously selling 7,000 shares in open-market transactions on July 15, 2026. She exercised 3,500 shares at $6.84 (cost $23,940) and 3,500 shares at $7.80 (cost $27,300) — total cash paid about $51,240. On the same date she sold 400, 2,497, 3,803 and 300 shares in multiple trades at weighted average prices of $84.36, $85.86, $86.68 and $87.25, respectively, for aggregate gross proceeds of approximately $603,937. The filing also reports two 3,500‑share derivative dispositions at $0 (reported as derivative disposals).

Key Details

• Transaction date: July 15, 2026.
• Exercises (acquired): 3,500 @ $6.84 ($23,940) and 3,500 @ $7.80 ($27,300) — total acquired 7,000 shares, total cost ~$51,240.
• Open-market sales (disposed): 400 @ $84.36; 2,497 @ $85.86; 3,803 @ $86.68; 300 @ $87.25 — weighted/average ranges noted in footnotes; total proceeds ~$603,937.
• Two derivative disposals of 3,500 shares each reported at $0 (listed as derivative dispositions) — filing notes vesting schedules for related option and warrant grants (see footnotes F6, F7).
• Sales were effected pursuant to a Rule 10b5‑1 trading plan entered September 19, 2025 (footnote F1).
• Weighted-average prices for the grouped sales are reported; the filing offers to provide per-trade price breakdowns on request (footnotes F2–F5).
• Shares owned after the transactions are not stated in the provided excerpt.
• Filing timeliness: Reported for period 2026-07-15 and filed same day — appears timely.

Context

• This was an exercise of derivatives (options/warrants) followed by open-market sales. Exercising options and selling shares the same day is commonly a cashless or monetization pattern; the two zero‑price derivative disposals may reflect net settlement, withholding or similar non‑cash disposition reported separately (filing does not elaborate).
• The open-market sales were made under a pre-established Rule 10b5‑1 plan, which is a prearranged program that schedules trades and can reduce the appearance of opportunistic timing.
• No speculative conclusions about motive or company outlook are made — the filing is factual reporting of insider activity.